Haemonetics HAE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Haemonetics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Haemonetics's additional paid-in capital?
- Haemonetics (HAE) reported additional paid-in capital of $554.14M in Q1 2026.
- How has Haemonetics's additional paid-in capital changed year-over-year?
- Haemonetics's additional paid-in capital increased by 5.9% year-over-year, from $523.26M to $554.14M.
- What is the long-term trend for Haemonetics's additional paid-in capital?
- Over 5 years (2021 to 2026), Haemonetics's additional paid-in capital has grown at a -1.7% compound annual growth rate (CAGR), from $602.73M to $554.14M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.